S&P Futures
4,161.00 +14.25 (+0.34%) Dow Futures
32,853.00 +96.00 (+0.29%) Nasdaq Futures
13,294.75 +66.00 (+0.50%) Russell 2000 Futures
1,927.20 +5.40 (+0.28%) Crude Oil
88.03 -0.98 (-1.10%) Gold
1,794.70 +3.50 (+0.20%)
Atara Biotherapeutics, Inc. (ATRA)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 3.3800 |
| Open | 3.3000 |
| Bid | 3.3100 x 3100 |
| Ask | 3.5100 x 1300 |
| Day's Range | 3.1701 - 3.4550 |
| 52 Week Range | 2.8300 - 20.0400 |
| Volume | |
| Avg. Volume | 2,023,787 |
| Market Cap | 321.316M |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.6450 |
| Earnings Date | Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ATRA
Related Research
- Atara Biotherapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 06/16/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., August 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 82,756 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 98,701 shares of Atara’s common stock to two such newly hired em
- Business Wire
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., August 03, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 9:00 a.m. PDT / 12:00 p.m. EDT.
- Zacks
Horizon (HZNP) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
Horizon's (HZNP) earnings and revenues lag estimates in the second quarter of 2022. The company lowers full-year revenue guidance for 2022. Shares were down in pre-market trading.
